The Top Healthcare Stocks of 2018: Can They Continue in 2019?
In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:
● How a game-changing new product sparked a 1,480% return in Tandem Diabetes;
● Why results from a long-awaited trial caused Amarin's shares to soar 239%;
● What caused Abiomed's shares to skyrocket 74%;
● And, the one blockbuster drug behind Merck's 36% rally higher in 2018.Subscribe to The Motley Fool's YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: